超低剂量地西他滨治疗老年骨髓增生异常综合征的疗效观察

目的分析超低剂量地西他滨治疗老年骨髓增生异常综合征（MDS）的临床疗效和安全性。方法回顾性分析41例MDs患者的临床资料；观察组（20例）单用地西他滨7—10mg/m2×3-5d方案，对照组（21例）单用地西他滨20mg／m2×5d方案。比较两组总有效率和不良反应发生率。结果观察组总有效率60．0％，对照组66．67％，差异无统计学意义（P〉0．05）。观察组Ⅳ°骨髓抑制、感染、心功能异常和出血发生率明显低于对照组，差异有统计学意义（P〈0．05）。结论超低剂量地西他滨治疗老年MDs的疗效与常规剂量相当，且安全性好。

Objective To analyze the clinical efficacy and safety of ultra low - dose decitabine in the treatment of elderly patients with myelodysplastic syndromes. Methods To retrospectively analyze the clinical data of 41 cases of MDS ; treatment group （ 20 cases ） was single use of decitabine 7-10mg/m2×3-5d program and control group （ 21 cases ） with decitabine 20mg/m2 × 5d program. The total effective rate and adverse reaction rate between the two groups were compared. Results The total effective rate of the treatment group was 60%, the control group was 66.67%, the difference was not statistically significant （ P〉0.05 ） . The incidence of grade IVmyelosuppression, infection, cardiac dysfunction and hemorrhage in the treatment group were significantly lower than that in the control group, the difference was statistically significant （ P〈0.05 ） . Conclusion The efficacy of ultra low - dose decitabine in the treatment of elderly patients with MDS is comparable to that of conventional dose, and the security is good.